Prevail Partners and Prevail InfoWorks Enter Into Strategic Investment and Clinical Alliance With Kairos Pharma, Ltd.

PHILADELPHIA, PA / ACCESSWIRE / September 25, 2024 / Prevail Partners LLC (“Prevail Partners”) and Prevail InfoWorks Inc. (“Prevail InfoWorks”) announce that they have entered into a strategic relationship with Kairos Pharma, Ltd. (“Kairos”), a clinical stage biopharmaceutical company located in Los Angeles, California, and the developer of innovative therapeutics that aim to reverse cancer resistance against standard of care therapeutics. Under the relationship, Prevail Partners, a life sciences investment fund, participated in the Initial Public Offering of Kairos, which became listed on the New York Stock Exchange on September 16, 2024.

Prevail InfoWorks, a global full-service Clinical Research Organization, has agreed to support Kairos with clinical services and technologies in two upcoming clinical trials: a phase II randomized multi-institutional trial of ENV 105 for patients with castrate-resistant prostate cancer and a phase I trial of ENV 105 in patients with EGFR-driven lung cancer who have developed partial or complete resistance to Osimertinib. Prevail InfoWorks will provide its Single InterfaceTM Integrated Analytics Platform and lead the project management for both trials, as well as provide site management, monitoring, and pharmacovigilance.

Mary Schaheen, President of Prevail Partners, said: “There is a substantial unmet need to address resistance to hormone and EGFR therapies for multiple cancer types that develop through the upregulation of CD105. Through our strategic investment and the clinical services of our affiliate, we are excited to support Kairos Pharma’s well-designed trials for testing INV 105, which aims to target CD105 signaling to reverse cancer drug resistance.”

About Prevail Partners, LLC

Prevail Partners, LLC is a corporate strategic investment fund investing in clinical stage therapeutics companies. More information is available at https://prevailpartners.com.

About Prevail InfoWorks, Inc.

Prevail InfoWorks, Inc. is a global full-service CRO/FSP and one-stop-shop for clinical trial services and systems. More information is available at https://prevailinfoworks.com.

About Kairos Pharma, Ltd.

Kairos Pharma, a clinical-stage biopharmaceutical company advancing therapeutics that reverse cancer drug resistance and immune suppression through the power of structural biology. More information is available https://kairospharma.com.

Contact Information

Henry Ehlers
Associate
henry.ehlers@prevailpartners.com
267-797-2043

SOURCE: Prevail Partners

View the original press release on newswire.com.

Staff

Recent Posts

Hemogenyx Pharmaceuticals PLC Announces IRB Approval for Phase I Clinical Trial

Hemogenyx Pharmaceuticals Receives IRB Approval for Phase 1 Clinical Trial of HEMO-CAR-T (HG-CT-1)LONDON, UK /…

35 minutes ago

Modular Medical Announces Pricing of $8.2 Million Public Offering

SAN DIEGO, CA / ACCESSWIRE / November 21, 2024 / Modular Medical, Inc. (Nasdaq:MODD) ("Modular…

4 hours ago

Nicole Garrett and Under Pressure Hyperbarics Lead the Charge in Wellness Education With Immersive Events at L.A. Fashion Weekend and Beyond

BEVERLY HILLS, CALIFORNIA / ACCESSWIRE / November 21, 2024 / Nicole Garrett, CEO of Under…

7 hours ago

Beacon Healthcare Systems Expands Leadership Team with Addition of Ayman Mohamed as Chief Technology Officer

HUNTINGTON BEACH, Calif., Nov. 21, 2024 /PRNewswire/ -- Beacon Healthcare Systems, is pleased to announce…

10 hours ago

Talkiatry Ranked Number 6 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™

Attributes Revenue Growth to Innovative Partnerships, Strong Team, and Unique Value-Based Care Model NEW YORK,…

10 hours ago

Bright Light Imaging Leverages Alpha Nodus’s Gravity Auth, Enhanced by Integration with ADS’s MedicsRIS, to Streamline Patient Care

Automation That Makes a Difference SUNRISE, Fla., Nov. 21, 2024 /PRNewswire/ -- When it comes…

10 hours ago